Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Great post Brighty1 which just confirms yet again the reason why so many investors are getting so enthused about Sareum. GSK certainly have the requisite funding to takeover Sareum or do a licencing deal. As Thoth pointed out GSK have ÂŁ8billion at their disposal for this. All the major global pharmaceutical companies will be aware of how effective the Sareum science is now. Lilly, Merck and AZ have participated in successful combos with SRA 737 and we have also been in trials with Dexamethasone, the results of which were outstanding. A major licencing deal is the next stage - which we could be hearing about imminently - but I wouldn't discount a takeover once the Covid data is published. Such a deal would take the Sareum share price in to the stratosphere. Hence why ÂŁ1+ really is a possibility with 20p very soon being my initial prediction.
Weren't we linked with GSK a few years back?
They probably tried to get us on the cheap, or thought we weren't far enough down the line with what we had
They can't say that now!
Noticed this when I read their report this morning. Like I said ... They are on a fishing expedition
Brighty1.
Absolutely fantastic post! If my thoughts are right then your post lifted from GSK nails my thoughts to a masthead.
The drop is imo manipulation by large fill orders not filled and thus not having to be reported.
I'm waiting for the derampers to pop in tonight.
If they do then just smile and let them speak to themselves and they can jog on.
Brighty. Quite. The Pharma division is getting ÂŁ8Bn from the sale of consumer for investment.
The core GSK Pharma portfolio has been hit by Covid delaying hospital treatments (tick).
I think there is more than one interested. but GSK definitely a fit
A couple of interesting paragraphs from the GSK update today, pasted below.
• Strategic focus to prevent and treat disease, with R&D leveraging science of the immune system, human genetics and advanced technologies = Tick for Sareum M&A / licencing
• The company is focused across four core therapeutic areas (TAs): Infectious Diseases, HIV, Oncology and Immunology/Respiratory. In addition, New GSK will remain open to opportunities outside these core TAs where there are scale opportunities rooted in immune science and genetic validation = Tick for Sareum M&A / licencing
• Capturing the increasing opportunities now seen across the prevention and treatment of disease offers significant scientific and commercial opportunities for New GSK. At the heart of this is the company's R&D focus on the science of the immune system, human genetics and advanced technologies; and its world-leading capabilities in vaccine and pharmaceutical development = Tick for Sareum M&A / licencing
I would suggest that GSK CEO Emma Walmsley and R&D boss, Dr Barron, need look no further than Sareum.
Good luck, Brighty
Absolutely. GSK is certainly on the hunt for new drugs and we do know that their R&D boss, Dr Barron, has links with directors of Sareum, so the GSK corporate jet could also be on the tarmac at Cambridge airport imminently. Interestingly, Berenberg in its latest note says that to make up for patent expiries GSK needs two new “megabusters” for their pipeline. We know where GSK could find one or two....
Good luck Sareum investors, Brighty.
Yes, it will certainly be very interesting to see if one of the private jets flying in to Cambridge (CBG) Airport this week has Pascal Soriot ceo of AstraZeneca on board. We know that SRA737 has been successful with Astra Zeneca's WEE1. Or there's the corporate jet of the new CEO of Merck MSD Robert Davis. We know that Merck's Keytruda in combo with Sareum's science causes the 100% regression in tumours. Merck MSD is still one of my top predictions, along with Eli Lilly, for a licencing or takeover with Sareum. Then again Paul Hudson, Chief Executive of Sanofi or Albert Bourla CEO of Pfizer could well be spotted at Cambridge Airport heading to Sareum's HQ very very soon.
All to play for. Here's to another key week for Sareum shareholders.
Good luck, Brighty
Hal Barron GSK's CSO & President, R&D and Luke Miels, COO are both in the UK this week from California and Australia for the GSK re-boot. Infact all the global GSK key board members are here in the UK for a few days. I wonder if a trip to Pampisford is part of their plans?
Soirot will often be in Cambridge anyway
And AZ have a daily shuttle from Cambridge Airport to Gothenburg - or at least did a couple of years ago - I used it every 2 or 3 weeks for a while. It's a small Sun Air jet in BA livery
I think Albert Bourla is already in the country as had meetings with Biden and others at the G7
I think we will need an observer at Cambridge (CBG) Airport in Taversham, just a few miles from the Sareum HQ, looking out for the the private jets flying in CEO’s such as:
Paul Hudson, Chief Executive of Sanofi,
Albert Bourla CEO of Pfizer,
Pascal Soriot ceo of AstraZeneca
Or my favourite for a deal with Sareum, Robert Davis the new CEO of Merck MSD
Or there could be Emma Walmsley ceo of GlaxoSmithKline arriving at the local bus stop.
Keep those eyes peeled….
Good luck, Brighty